CARGO Therapeutics (CRGX) Q2 2025 earnings summary

Executive summary

• Discontinued lead Phase 2 study and suspended all pipeline development, resulting in a 90% workforce reduction and major restructuring in early 2025.

• Entered into a merger agreement with Concentra Biosciences in July 2025, with a cash tender offer and contingent value rights for shareholders.

• If the merger is not completed, alternatives include dissolution and liquidation or other strategic transactions.

Financial highlights

• Net loss of $49.9M for Q2 2025, compared to $44.3M in Q2 2024; net loss of $134.4M for the first half of 2025, up from $80.2M year-over-year.

• Operating expenses rose to $52.9M in Q2 2025 from $49.3M in Q2 2024, driven by $37.1M in restructuring and impairment costs.

• Cash, cash equivalents, and marketable securities totaled $252.6M as of June 30, 2025.

• Accumulated deficit reached $447.1M as of June 30, 2025.

• Interest income decreased to $3.3M in Q2 2025 from $5.0M in Q2 2024 due to lower average balances.

Outlook and guidance

• Operating expenses expected to decrease for the remainder of 2025 due to workforce reductions and program suspensions.

• Cash runway projected to support operations for at least 12 months from the financial statement issuance date.

• Completion of the merger is uncertain; if not completed, the board may pursue liquidation or alternative transactions.